🔒 A year of obesity drug hype: What was missed – Lisa Jarvis
In a year marked by the transformative potential of obesity medications, the discourse surrounding these drugs has been trapped in polarising
In a year marked by the transformative potential of obesity medications, the discourse surrounding these drugs has been trapped in polarising
The rising costs and uncertainties surrounding the long-term use of obesity drugs have become a significant concern for both patients and healthcare systems.
Semaglutide, a drug marketed as Wegovy or Ozempic, was initially developed for diabetic patients to control blood sugar levels but has gained attention for its potential weight loss effects.
The article discusses the “Obesity Industrial Complex” and how various industries collaborate to profit from obesity-related issues.
An analysis of data in Mpumalanga has identified the highest risk populations for Covid-19 as those with HIV, hypertension, diabetes, TB and obesity.
The proposed tax on sugar-sweetened beverages is no quick fix for South Africa’s complex obesity problem, writes Anthea Jeffery of the Institute of Race Relations.
Real food is the answer to the obesity crisis sweeping the planet, says British researcher and author Zoë Harcombe.
By Sharon Begley NEW YORK – That obesity can cut life short by causing strokes and other illnesses comes as no surprise, but a new study quantifies the toll: The most extreme cases cut a person’s lifespan more than cigarettes are able to do. The analysis, published in the journal PLOS (Public Library of Science) Medicine, … Read more
BizNews brainteaser returns with another edition of Ian’s Trivialus. For a trivia enthusiast or if you simply love learning new things.